A Closer Look at the Role of CDK4/6 Inhibitors
in Hormone Positive Breast Cancer

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Novartis Pharmaceuticals

There is no single treatment strategy that will work for all patients with metastatic breast cancer (MBC). Instead, treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life. Effective and timely treatment of metastatic breast cancer can greatly extend and improve quality of life. Tremendous strides are being made in the treatment of both hormone-positive and hormone-negative disease, as well as for patients with specific tumor subtypes. Surgery, chemotherapy, radiation therapy, endocrine therapy, and targeted therapies are some of the options that oncologists have available at their disposal. Depending on multiple factors including age, health and where the disease has metastasized, oncologists can pick the most appropriate option from an assortment of treatments. Fortunately for advanced breast cancer patients, several new agents that inhibit two proteins called cyclin dependent kinase (CDK) 4 and 6 are currently undergoing late stage clinical trials. They have shown the ability to vastly improve safety and efficacy outcomes, especially in the area of HR+, HER2-Negative metastatic breast cancer. Healthcare professionals are now able to create a customized therapeutic approach that focuses on patient factors and tumor characteristics, which provides patients with improved outcomes and quality of life.

Upon Completion of this activity, participants will be able to:

  • Review the efficacy, safety, and survival prolongation profiles of emerging CDK4/6 inhibitors for the treatment of advanced breast cancer

  • Analyze recent clinical data on novel CDK4/6 inhibitors from late stage clinical trials and how they might be integrated into the treatment paradigm

  • Correlate the mechanistic activity of emerging CDK4/6 inhibitors with the rationale for their use as targeted therapy for HR+ advanced breast cancer

  • Evaluate unmet needs in treating patients with advanced breast cancer, including future applications of CDK4/6 inhibitors

  • Identify strategies for the mitigation and management of predictable adverse events associated with emerging CDK4/6 inhibitor therapies in the management of advanced breast cancer

Faculty: George Somlo, MD
City of Hope
Department of Medical Oncology and Therapeutics Research and Hematology
Department of Hematopoietic Cell Transplantation


Dr. Somlo serves in a consulting/advisory capacity for AbbVie, AstraZeneca, Celgene, Genentech, Nanostring, Novartis and Pfizer; receives research support from Celgene and Genentech and is on the speaker's bureau for Takeda Oncology. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue